prior
develop
therapeut
regim
base
molecular
mechan
diseas
caus
agent
isol
analys
soon
fast
establish
intern
laboratori
network
rapid
progress
made
identif
process
caus
agent
report
sar
probabl
caus
novel
strain
famili
coronavirus
virus
commonli
known
caus
respiratori
gastrointestin
diseas
human
domest
anim
group
coronavirus
classifi
member
order
nidoviral
repres
group
envelop
positivesens
rna
virus
consist
coronavirida
arterivirida
virus
group
known
synthes
cotermin
set
subgenom
mrna
infect
cell
soon
identif
new
coronaviru
caus
agent
sar
southern
chines
provinc
first
area
occurr
anim
speci
area
specul
origin
sarscov
analysi
sarscov
genet
sequenc
reveal
larg
differ
current
known
coronavirus
human
domest
anim
hypothes
new
viru
might
origin
wild
anim
hypothesi
support
search
coronavirus
wild
anim
sold
market
southern
china
identifi
presenc
coronaviru
civet
cat
anim
coronaviru
shown
sequenc
ident
sar
coronaviru
limit
number
delet
mutat
virus
sarscov
delet
nucleotid
rel
civet
cat
viru
indic
direct
transmiss
went
anim
man
delet
occur
probabl
easili
insert
recent
report
indic
sarscov
distinct
civet
cat
viru
answer
far
civet
cat
viru
origin
sarscov
civet
cat
also
infect
speci
therefor
data
avail
possibl
horizont
transmiss
anim
question
whether
jump
viru
anim
human
singl
accid
may
frequent
occur
futur
anim
danger
reservoir
futur
sar
epidem
remain
unansw
far
sarscov
report
abl
infect
human
also
macaqu
monkey
domest
cat
ferret
howev
transmiss
viru
domest
cat
man
shown
abil
sarscov
infect
anim
speci
could
point
potenti
natur
reservoir
viru
respect
coronavirus
known
rel
easili
jump
speci
ie
human
coronaviru
share
high
degre
genet
sequenc
homolog
bovin
coronaviru
bcov
commonli
assum
jump
one
speci
way
bcov
report
abl
infect
human
caus
diarrhea
wherea
precis
mechan
speci
jump
remain
unclear
like
repres
result
mutat
epidemiolog
studi
coronaviru
infect
wild
anim
therefor
crucial
futur
understand
control
new
sar
outbreak
identif
new
sarscov
coronavirus
divid
three
subgroup
differ
respect
genom
first
group
consist
virus
human
coronaviru
porcin
respiratori
coronaviru
prcv
porcin
transmiss
gastroenter
viru
tgev
felin
infecti
periton
viru
fipv
felin
enter
viru
fev
canin
coronaviru
ccov
second
group
compris
human
coronaviru
bovin
coronaviru
bcov
mous
hepat
viru
mhv
third
group
mainli
consist
avian
speci
chicken
infecti
bronchiti
viru
ibv
wherea
sarscov
shown
crossreact
group
coronaviru
antibodi
genet
sequenc
belong
group
within
nucleic
acid
protein
sequenc
phylogenet
tree
coronaviru
famili
sarscov
first
locat
equal
distanc
second
third
group
irrespect
sarscov
rna
region
use
analysi
therefor
sarscov
may
repres
first
member
new
group
coronavirus
figur
howev
taxonomi
still
clear
recent
studi
focus
ntermin
domain
spike
protein
poorli
conserv
protein
matrix
protein
nucleocapsid
suggest
relat
group
ii
virus
similar
conclus
drawn
polymeras
gene
examin
point
earli
splitoff
coronaviru
group
lineag
despit
fact
new
viru
like
jump
human
wild
anim
speci
remark
well
adapt
human
organ
shown
high
persontoperson
transmiss
structur
sar
viral
rna
organ
open
read
frame
orf
contain
total
approxim
nucleotid
recent
sarscov
sequenc
deriv
earli
middl
late
phase
sar
epidem
togeth
two
viral
sequenc
palm
civet
analyz
genotyp
characterist
phase
discov
found
neutral
mutat
rate
viral
genom
constant
amino
acid
substitut
rate
code
sequenc
slow
cours
epidem
spike
protein
show
strongest
initi
respons
posit
select
pressur
orf
exceed
fifti
amino
acid
translat
capac
consid
relev
contain
sequenc
structur
function
properti
viru
therefor
potenti
interest
develop
futur
therapeut
strategi
comparison
differ
sarscov
orf
coronavirus
reveal
familiar
pattern
structur
gene
arrang
replicas
proteas
gene
gene
spike
envelop
e
membran
nucleocapsid
n
gene
typic
order
appear
protein
encod
gene
may
target
novel
treatment
wellknown
gene
seri
orf
unknown
function
found
two
orf
situat
spike
envelop
gene
three
five
orf
membran
nucleocapsid
gene
comparison
gene
organ
known
coronavirus
indic
closest
proxim
group
ii
coronavirus
also
sarscov
genom
sequenc
contain
gene
hemagglutininesteras
protein
present
major
group
ii
coronavirus
twothird
sar
rna
organ
gene
sequenc
gene
highli
conserv
among
coronavirus
orf
encod
two
polyprotein
latter
ribosom
frameshift
mechan
polyprotein
process
virusencod
proteinas
yield
individu
protein
potenti
gene
product
fairli
well
conserv
sarscov
coronavirus
mani
function
unknown
suggest
particip
viral
rna
replic
make
potenti
target
develop
antivir
compound
therefor
research
effort
focu
protein
one
except
overal
conserv
sarscov
gene
lack
sequenc
code
one
two
papainlik
proteinas
oper
cleavag
site
nterminu
polyprotein
figur
main
proteinas
mpro
also
call
proteas
respons
cleavag
remain
protein
encod
gene
apart
gene
coronaviru
gene
known
usual
express
subgenom
mrna
share
common
leader
sequenc
initi
differ
place
genom
extend
toward
viru
genom
orf
may
also
unconvent
translat
singl
mrna
uncommon
translat
mechan
effici
gene
product
abund
orf
typic
encod
nonstructur
protein
wherea
orf
structur
protein
gene
heterogen
among
differ
coronavirus
essenti
viral
replic
recent
studi
suggest
delet
nonessenti
orf
may
result
reduc
virul
agreement
nonessenti
orf
new
sarscov
genom
may
respons
high
sarscov
virul
far
five
eight
subgenom
mrna
found
sarscovinfect
cell
thiel
colleagu
perform
first
detail
studi
mechan
enzym
involv
sarscov
genom
express
figur
determin
sequenc
sarscov
isol
frankfurt
character
major
rna
element
protein
function
involv
genom
express
character
regulatori
mechan
discontinu
synthesi
eight
subgenom
mrna
ribosom
frameshift
posttransl
proteolyt
process
also
activ
sarscov
enzym
helicas
two
cystein
proteinas
mpro
address
involv
replic
transcript
posttransl
polyprotein
process
conclus
research
area
coronaviru
gene
express
import
delin
compon
directli
affect
sarscov
virul
structur
protein
new
sarscov
potenti
target
new
treatment
option
new
sarscov
contain
three
envelop
protein
spike
envelop
e
membran
hemagglutininesteras
protein
present
coronavirus
second
group
spike
glycoprotein
respons
characterist
spike
sarscov
figur
intra
extracellular
proteas
often
cleav
protein
domain
cleavag
process
often
increas
infect
viru
molecular
model
perform
unit
sarscov
spike
protein
spike
protein
coronavirus
report
bind
receptor
target
cell
domain
respons
receptorbind
commonli
situat
ntermin
region
spike
consist
oligomer
structur
form
heptad
repeat
domain
also
repres
fusion
peptid
sequenc
peptid
respons
coronaviru
fusion
activ
sarscov
also
report
caus
format
syncytia
vivo
far
condit
cultur
vero
cell
sarscov
protein
seem
characterist
common
protein
coronavirus
import
understand
sarscov
pathogen
properti
identifi
exact
condit
membran
fusion
ie
ph
depend
proteas
sensit
increas
infect
envelop
membran
protein
integr
membran
protein
requir
viru
assembl
case
murin
coronaviru
coexpress
e
protein
n
protein
need
releas
viruslik
particl
vlp
nucleocapsid
viral
core
sarscov
like
form
n
protein
interest
featur
sarscov
coronavirus
resist
gastrointestin
fluid
despit
lipid
composit
envelop
report
sarscov
surviv
diarrheal
stool
four
day
also
patient
sar
often
suffer
gastrointestin
symptom
viru
detect
stool
molecular
basi
envelop
resist
acid
environ
gastrointestin
enzym
unclear
research
carri
area
import
control
futur
sar
outbreak
unclear
novel
pathogen
sarscov
cross
barrier
natur
reservoir
human
popul
lead
epidem
spread
novel
infecti
diseas
sarscov
new
pathogen
believ
emerg
anim
reservoir
varieti
molecular
mechan
may
contribut
evolut
virus
bacteria
due
estim
error
frequenc
rnadepend
rna
polymeras
rna
virus
sarscov
undergo
mutat
high
frequenc
sarscov
seem
rel
genet
stabl
rna
sequenc
differ
sar
patient
quit
homogen
even
entir
genom
sequenc
viru
isol
differ
continent
area
differ
ten
amino
acid
seem
two
lineag
viru
trace
obviou
contradict
high
potenti
error
rate
rnadepend
rna
polymeras
suggest
presenc
proofread
mechan
connect
enzym
fact
detail
analysi
sarscov
genom
bioinformat
indic
presenc
exonucleas
activ
next
mutat
threat
sarscov
base
abil
coronavirus
undergo
rna
recombin
high
frequenc
varieti
coronavirus
recombin
mutat
natur
infect
shown
contribut
diversif
coronavirus
demonstr
abil
coronavirus
recombin
question
whether
sarscov
show
higher
frequenc
mutat
within
possibl
futur
season
chang
respond
drug
treatment
issu
major
concern
report
initi
phase
sar
epidem
mutat
rate
high
gene
spike
protein
stabil
middl
final
stage
epidemi
thu
viru
experienc
great
pressur
adapt
new
host
cross
speci
barrier
optim
although
human
coronavirus
characterist
caus
selflimit
short
diseas
question
potenti
chronic
sar
infect
major
import
futur
diseas
control
sarscov
abl
caus
chronic
persist
infect
chronic
carrier
may
serv
sourc
new
sar
outbreak
howev
detect
sarscov
stool
patient
longer
period
week
hospit
discharg
report
far
therefor
danger
chronic
carrier
may
relev
contrast
common
human
coronaviru
infect
short
durat
anim
coronavirus
caus
persist
infect
exampl
felin
coronaviru
fipv
infect
anim
continu
shed
viru
period
reach
seven
month
infect
without
carri
diseas
symptom
also
tgev
mhv
tend
caus
chronic
infect
virus
may
found
airway
small
intestin
tgev
nervou
system
mhv
sever
month
infect
although
sarscov
jump
human
may
still
properti
induc
chronic
infect
thu
sarscov
rna
found
patient
stool
specimen
day
infect
mean
incub
period
sar
estim
day
confid
interv
mean
report
time
onset
clinic
symptom
hospit
admiss
vari
three
five
day
main
clinic
featur
diseas
initi
period
common
symptom
persist
fever
myalgia
chill
dri
cough
dizzi
headach
although
less
common
symptom
sore
throat
sputum
product
coryza
vomit
nausea
diarrhea
special
attent
paid
symptom
diarrhea
wateri
diarrhea
also
report
subgroup
patient
one
week
initi
symptom
clinic
cours
diseas
seem
follow
bi
triphas
pattern
first
phase
viral
replic
increas
viral
load
fever
myalgia
system
symptom
found
symptom
gener
improv
day
second
phase
repres
immunopatholog
imbal
major
clinic
find
oxygen
desatur
recurr
fever
clinic
radiolog
progress
acut
pneumonia
second
phase
concomit
fall
viral
load
major
patient
known
respond
second
phase
treatment
howev
patient
may
progress
third
critic
phase
phase
character
develop
acut
respiratori
distress
syndrom
ard
commonli
necessit
mechan
ventil
rapid
progress
made
understand
clinic
present
sar
adult
children
comparison
adult
sar
seem
less
aggress
younger
children
children
one
case
seri
requir
supplementari
oxygen
adult
system
infect
well
respiratori
infect
may
rule
sar
much
milder
nonspecif
coldlik
symptom
children
younger
year
adolesc
adult
reason
milder
clinic
present
sar
children
like
due
differ
development
stage
immun
system
cours
diseas
teenag
like
resembl
adult
concern
clinic
present
diseas
progress
sar
may
also
develop
sever
ill
requir
intens
care
assist
ventil
adolesc
patient
common
present
featur
fever
malais
coryza
cough
chill
rigor
headach
myalgia
leucopaenia
thrombocytopaenia
lymphopaenia
elev
lactat
dehydrogenas
level
mildli
prolong
activ
partial
thromboplastin
time
radiograph
find
nonspecif
howev
highresolut
comput
chest
tomographi
clinic
suspect
case
may
prove
earli
diagnost
aid
initi
chest
radiograph
appear
normal
rapid
diagnosi
firstgener
rtpcr
assay
satisfactori
improv
rtpcr
assay
may
help
diagnos
sar
earli
stage
respect
sensit
approach
first
day
ill
perform
nasopharyng
aspir
may
achiev
best
treatment
strategi
sar
among
children
still
determin
case
fatal
report
children
comparison
prognosi
adult
rel
good
short
mediumterm
outcom
howev
crucial
emphas
continu
monitor
longterm
complic
due
diseas
treatment
major
import
coronavirus
known
exert
effect
cytocid
immunemedi
mechan
vitro
studi
use
cell
cultur
assay
shown
coronaviru
infect
commonli
result
cytopath
effect
cellular
lysi
apoptosi
also
viru
caus
cellular
fusion
lead
format
syncytia
cytopath
effect
caus
step
viral
replic
mobilis
vesicl
form
viral
replic
complex
lead
disrupt
golgi
complex
parallel
result
coronavirus
sarscov
shown
caus
cytopath
effect
vero
cell
format
syncytia
lung
tissu
similar
coronavirus
seem
potenti
sarscov
caus
tissu
fibrosi
molecular
mechan
fibrosi
report
infect
coronaviru
mhv
n
protein
demonstr
induc
promot
activ
prothrombinas
gene
correl
fibrin
deposit
next
cytocid
effect
also
immunemedi
mechan
innat
adapt
immun
system
seem
contribut
pathogenesi
sarscov
infect
respect
shown
mhv
infect
cell
cytokin
play
import
role
develop
diseas
also
humor
antibodi
report
crucial
infect
caus
coronavirus
fipv
herein
antibodi
spike
protein
shown
relat
induct
periton
sarscov
infect
report
seem
inflammatori
cell
influx
consist
particular
macrophag
airway
massiv
releas
cytokin
peak
infect
therefor
crucial
immun
mechan
analys
molecular
level
seem
appropri
antivir
also
antiinflammatori
strategi
evalu
use
clinic
manag
futur
sar
case
pharmacotherapi
sar
antiinflammatori
steroid
controversi
larg
anecdot
report
initi
use
puls
methylprednisolon
therapi
appear
efficaci
equal
safe
compar
regimen
lower
dosag
therefor
consid
prefer
steroid
regimen
treatment
sar
pend
data
futur
random
control
trial
preliminari
uncontrol
studi
patient
sar
report
use
interferon
plu
steroid
associ
reduc
diseaseassoci
impair
oxygen
satur
rapid
resolut
radiograph
lung
abnorm
obviou
gene
like
key
modifi
sar
pathomechan
spike
protein
gene
known
coronavirus
affect
viral
pathogenesi
determin
target
cell
specif
also
mechan
respect
singl
mutat
gene
mhv
signific
effect
viral
virul
tissu
tropism
also
mutat
gene
led
emerg
weakli
virul
prcv
virul
enter
tgev
potenti
import
gene
nonessenti
orf
show
signific
diverg
sarscov
coronavirus
respect
report
civet
cat
coronaviru
delet
lead
fusion
two
nonessenti
orf
one
new
orf
sarscov
shown
delet
mutant
nonessenti
orf
group
mous
hepat
viru
mhv
lead
lower
virul
without
impact
viral
replic
establish
also
appli
nonessenti
orf
sarscov
also
viral
gene
product
e
protein
may
impact
pathogenesi
diseas
may
induc
interferon
product
apoptosi
primari
target
cell
sarscov
infect
respiratori
epitheli
cell
viru
also
detect
stool
specimen
patient
sar
often
also
gastrointestin
symptom
epitheli
cell
gastrointestin
tract
also
seem
major
target
cell
next
epitheli
cell
sarscov
also
found
macrophag
mani
cell
detect
respiratori
tract
stool
specimen
also
blood
liver
kidney
urin
respect
patholog
examin
show
chang
respiratori
tract
also
splenic
lymphoid
tissu
lymph
node
furthermor
sign
system
vascul
found
includ
edema
local
fibrinoid
necrosi
infiltr
monocyt
lymphocyt
plasma
cell
vessel
wall
heart
lung
liver
kidney
adren
gland
stroma
striat
muscl
also
thrombosi
present
vein
system
toxic
chang
includ
necrosi
degener
parenchym
cell
lung
heart
liver
kidney
adren
gland
may
therefor
conclud
sar
induc
system
diseas
therebi
injur
mani
organ
apart
respiratori
tract
sarscov
target
cell
specif
determin
spike
protein
affin
cellular
receptor
contrast
group
iii
coronavirus
sarscov
receptor
final
analyz
known
group
coronavirus
bind
aminopeptidas
n
receptor
group
ii
coronaviru
mhv
use
carcinoembryon
antigen
cea
receptor
recent
shown
metallopeptidas
angiotensinconvert
enzym
effici
bind
domain
sarscov
protein
sarscov
replic
effici
mocktransfect
cell
also
antibodi
block
viral
replic
vero
cell
indic
function
receptor
sarscov
also
identifi
studi
recent
ctype
lectin
also
call
lsign
discov
human
cellular
glycoprotein
serv
altern
receptor
sarscov
interrupt
virusreceptor
interact
could
potenti
target
futur
therapeut
strategi
figur
respect
receptorbind
domain
sarscov
protein
repres
possibl
target
new
sar
antivir
drug
also
antibodi
inhibitor
bind
activ
site
may
use
develop
therapeut
strategi
bind
receptor
next
molecular
step
potenti
use
develop
antisar
drug
viru
entri
cell
coronavirus
enter
target
cell
via
plasma
membran
fusion
entri
mechan
may
acid
phdepend
endocytosi
focus
mechan
crucial
gain
knowledg
sarscov
fusion
activ
drug
develop
candid
put
fusion
peptid
good
potenti
figur
bind
host
cell
receptor
entri
cell
molecular
step
transcript
translat
protein
process
display
potenti
target
new
therapeut
strategi
respect
rnadepend
rna
polymeras
sarscov
rdrp
may
potenti
target
futur
antisar
therapi
recent
studi
locat
conserv
motif
built
threedimension
model
catalyt
domain
author
suggest
potenti
antisarscov
rdrp
nucleotideanalog
inhibitor
featur
hydrogenbond
capabl
group
sugar
ring
endo
sugar
pucker
also
absenc
hydrophob
bind
pocket
nonnucleosid
analog
inhibitor
similar
observ
hepat
c
viru
rdrp
human
immunodefici
viru
type
revers
transcriptas
seem
crucial
also
proteas
activ
crucial
sarscov
rna
replic
protein
process
inhibit
proteas
function
lead
immedi
stop
viral
rna
synthesi
coronavirus
express
one
major
cystein
proteinas
call
main
proteinas
mpro
proteinas
two
auxiliari
papainlik
proteinas
latter
two
respons
cleavag
viral
polyprotein
three
site
near
aminoterminu
mpro
process
protein
mani
addit
site
interestingli
sarscov
lack
assum
action
taken
conceiv
sinc
oper
cleavag
site
shown
ibv
hcov
roughli
posit
gene
coronaviru
genom
sarscov
display
domain
within
lack
detect
sequenc
homolog
therefor
name
sarsuniqu
domain
sud
known
whether
sud
protein
ever
express
life
cycl
sarscov
may
connect
high
pathogen
sarscov
compar
human
coronavirus
therefor
may
constitut
attract
target
therapeut
intervent
crystal
structur
determin
mpro
tgev
hcov
recent
sarscov
show
similar
overal
architectur
kd
enzym
form
dimer
crystal
also
intermedi
high
concentr
solut
monom
consist
three
domain
first
two
overal
similar
proteinas
picornavirus
serin
proteinas
chymotrypsin
third
domain
shown
essenti
dimer
activ
site
enzym
locat
cleft
domain
ii
compris
catalyt
dyad
cy
rather
catalyt
triad
common
cystein
serin
proteinas
anand
et
al
synthes
substrateanalog
hexapeptidyl
chloromethylketon
inhibitor
bound
tgev
mpro
crystallin
state
xray
structur
complex
reveal
bind
glutamin
leucin
threonin
side
chain
compound
respect
subsit
substratebind
cleft
agreement
pronounc
specif
cleavag
mpro
substrat
sequenc
thr
val
ser
xaaleugln
structur
also
show
expect
coval
attach
methyl
keton
group
inhibitor
catalyt
cystein
enzym
spite
sequenc
ident
respect
mpro
hcov
tgev
crystal
structur
sarscov
mpro
reveal
surpris
within
dimer
one
molecul
activ
conform
seen
structur
wherea
one
adopt
catalyt
incompet
conform
enzym
crystal
ph
valu
one
monom
appar
led
proton
histidin
residu
bottom
specif
pocket
result
major
conform
rearrang
lead
collaps
bind
site
glutamin
residu
substrat
catalyt
incompet
conform
oxyanionbind
loop
howev
crystal
equilibr
higher
ph
valu
xray
structur
reveal
activ
conform
monom
dimer
phdepend
activ
mechan
allow
interest
conclus
made
selfactiv
mpro
viral
polyprotein
probabl
involv
phdepend
step
hexapeptidyl
chloromethylketon
inhibitor
use
anand
et
al
crystallograph
studi
tgev
mpro
employ
yang
et
al
character
interact
sarscov
enzym
substrat
perform
soak
inhibitor
crystal
grown
low
ph
spite
inact
conform
one
two
monom
dimer
preserv
compound
found
bind
glutamin
side
chain
point
toward
bulk
solvent
rather
bind
site
collaps
latter
bind
mode
inhibitor
activ
monom
also
somewhat
unusu
fulli
understood
present
basi
crystallograph
work
anand
et
al
found
bind
mode
hexapeptidyl
chloromethylketon
inhibitor
tgev
mpro
resembl
complex
target
proteinas
human
rhinoviru
even
though
respect
target
enzym
display
larg
structur
differ
except
immedi
neighbourhood
activ
site
phase
iiiii
clinic
studi
inhal
treatment
common
cold
caus
human
rhinoviru
anand
et
al
therefor
propos
good
start
point
design
antisar
drug
inde
manufactur
confirm
day
propos
appear
onlin
compound
effect
sar
coronaviru
cell
cultur
subject
intens
optim
effort
studi
use
molecular
dynam
simul
mpro
screen
approv
experiment
drug
model
sar
cov
proteinas
well
experiment
structur
transmiss
gastroenter
viru
tgev
proteinas
suggest
exist
proteas
inhibitor
instanc
may
high
bind
affin
may
therefor
provid
anoth
good
start
point
futur
design
sarscov
proteinas
inhibitor
howev
prove
experiment
potenti
target
e
protein
figur
repres
minimum
essenti
compon
assembl
coronavirus
form
viruslik
particl
ultrastructur
process
sarscov
assembl
like
localis
ergolgi
intermedi
compart
togeth
strategi
may
focu
inhibit
viru
assembl
viru
exit
secretori
pathway
also
interest
develop
new
antivir
compound
regard
multitud
potenti
epitheli
target
cell
specif
endogen
drug
deliveri
system
may
also
relev
respect
famili
peptid
transport
consist
differenti
express
potenti
infect
cell
respiratori
tract
small
intestin
kidney
nervou
system
organ
may
serv
target
ration
drug
design
antivir
drug
far
varieti
antivir
drug
prodrug
valacyclovir
valganciclovir
valyl
ester
zidovudin
shown
transport
via
system
minim
structur
requir
substrat
transport
determin
tool
may
use
approach
antivir
therapi
techniqu
small
interf
rna
sirna
sirna
doublestrand
rna
lead
sequencespecif
degrad
mrna
recent
vitro
studi
use
six
sirna
target
differ
site
replicas
region
sarscov
monkey
kidney
cell
infect
sarscov
strain
transfect
eight
hour
later
sirna
three
six
sirna
led
mark
inhibit
viru
cytopath
effect
reduct
viru
copi
indic
sirna
may
potenc
antivir
treatment
option
region
display
promis
region
suppress
viru
replic
patient
develop
immun
sarscov
surviv
infect
possibl
creat
effect
safe
vaccin
seem
exist
sever
option
develop
vaccin
sarscov
liveattenu
coronaviru
vaccin
gener
delet
groupspecif
gene
delet
gene
chang
replic
properti
attenu
viru
exampl
use
liveattenu
vaccin
prevent
coronaviru
infect
live
attenu
ibv
vaccin
use
broiler
chicken
anim
coronaviru
infect
live
attenu
vaccin
proven
significantli
effect
whole
kill
vaccin
indic
cellmedi
immun
crucial
defenc
mechan
howev
great
threat
remain
vaccin
strain
recombin
circul
wild
type
strain
without
evid
recombin
revers
liveattenu
sarscov
virul
occur
unlik
live
attenu
sarscov
vaccin
develop
use
whole
kill
vaccin
gener
safe
easi
gener
fact
techniqu
appli
veterinari
medicin
gener
vaccin
bocv
ibv
also
inactiv
canin
coronaviru
vaccin
produc
sar
inactiv
vaccin
recent
develop
use
sar
coronaviru
sarscov
strain
treat
formaldehyd
mix
al
oh
howev
kill
vaccin
may
protect
differ
strain
coronavirus
live
attenu
vaccin
shown
effect
whole
kill
vaccin
prevent
coronaviru
anim
infect
use
molecular
biolog
techniqu
gener
larg
quantiti
recombin
viral
protein
recombin
subunit
vaccin
eg
spike
protein
expect
creat
rel
easi
shown
two
recent
studi
eight
recombin
human
singlechain
variabl
region
fragment
scfv
domain
spike
protein
sarscov
two
nonimmun
human
antibodi
librari
screen
one
scfv
effici
neutral
sarscov
inhibit
syncytia
format
cell
express
protein
express
sarscov
receptor
angiotensinconvert
enzym
recent
studi
use
sarscov
spike
protein
receptor
bind
domain
aa
immun
result
induct
effect
neutral
antibodi
howev
recombin
subunit
vaccin
may
limit
abil
protect
sarscov
infect
view
variat
may
aris
viral
genom
futur
outbreak
therefor
approach
recombin
subunit
vaccin
may
supplement
vaccin
strategi
focu
cellmedi
immun
approach
use
recombin
vector
vaccin
dna
viral
vector
could
promis
target
dna
prime
adenoviru
mva
boost
approach
current
analys
potenti
use
develop
hiv
vaccin
may
also
offer
strategi
prevent
sar
infect
respect
multival
approach
induc
humor
cellmedi
host
respons
seem
attract
strategi
field
veterinari
medicin
data
approach
alreadi
avail
recombin
fowlpox
gene
ibv
demonstr
rel
protect
ibv
also
dna
vaccin
develop
contain
nucleocapsid
protein
gene
porcin
transmiss
gastroenter
viru
ptgv
vaccin
shown
initi
humor
cellmedi
immun
host
respons
recent
three
murin
studi
demonstr
dna
vaccin
encod
differ
sarscov
antigen
capabl
gener
humor
cellular
immun
may
potenti
use
control
infect
sarscov
howev
also
shown
immun
modifi
vaccinia
viru
ankarabas
recombin
vaccin
sar
associ
enhanc
hepat
ferret
strategi
base
use
epitop
deliv
use
viral
dna
vector
epitopebas
strategi
coronaviru
vaccin
alreadi
report
major
advantag
prevent
possibl
vaccin
revers
virul
benefit
techniqu
possibl
elimin
region
viral
genom
sequenc
associ
potenti
autoimmun
effect
limit
approach
mainli
base
potenti
variat
respect
epitop
frequent
undergo
mutat
protect
sarscov
infect
use
epitopebas
vaccin
sarscov
evolv
highli
variabl
viru
crucial
identifi
highli
conserv
epitop
viru
summari
import
develop
sar
vaccin
approach
use
sever
techniqu
ideal
encompass
induct
humor
cellmedi
mechan
coronaviru
vaccin
anim
partli
report
caus
enhanc
viral
infect
cautiou
approach
follow
first
studi
investig
abil
adenovir
deliveri
codonoptimis
sarscov
spike
protein
fragment
membran
protein
nucleocapsid
protein
induc
immun
rhesu
macaqu
immun
combin
three
vector
booster
vaccin
day
demonstr
antibodi
respons
spike
protein
fragment
also
tcell
respons
nucleocapsid
protein
found
vaccin
anim
display
strong
neutralis
antibodi
respons
vitro
result
indic
adenoviralbas
vaccin
induc
sarscovspecif
immun
respons
monkey
summari
onset
sar
epidem
differ
contin
led
format
success
laboratori
network
identifi
molecular
mechan
underli
sar
infect
next
develop
earli
diagnost
test
effect
treatment
strategi
import
orchestr
research
activ
lead
develop
vaccin
antivir
agent
establish
therapi
date
even
situat
hand
new
case
sar
remain
major
global
health
hazard
may
reappear
